Fig. 5: del(5q) MDS cells depleted of TP53 or RUNX1 are sensitive to Abl or MAPK inhibitors. | Leukemia

Fig. 5: del(5q) MDS cells depleted of TP53 or RUNX1 are sensitive to Abl or MAPK inhibitors.

From: Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

Fig. 5

GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC (A), BIOCARTA_MAPK (B), and BIOCARTA_MTOR (C) pathways in MDS patient CD34+ bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells (G) and MDS-L (H). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).

Back to article page